<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375411</url>
  </required_header>
  <id_info>
    <org_study_id>17-1036</org_study_id>
    <nct_id>NCT03375411</nct_id>
  </id_info>
  <brief_title>First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.</brief_title>
  <official_title>INCSTENT First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GALAZ SCIENCE AND ENGINEERING SA DE CV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medstent SA de CV.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Cardiologia Ignacio Chavez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First In Man study with the aim to know the safety and effectiveness of a novel
      bare metal stent (INC-1) in the treatment of de novo coronary lesions in patients with stable
      coronary angina and unique coronary lessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cost of performing a percutaneous coronary intervention is very variable since a large
      number of materials and human resources are considered, with the Stent cost being a
      fundamental factor; in developing countries, the cost this technology represents an important
      expense for the patient and the health system; which promotes the development of local
      technology to support the requirement of these devices.

      Ischemic heart disease together with cerebral vascular events is the main cause of, adding 15
      million deaths per year. Percutaneous revascularization is the gold standard choice in many
      of the variants of presentation of ischemic heart disease, the implantation of Stents is the
      most used method.

      Nowadays more and more countries start their own research and development of novel devices in
      order to reduce cost.

      Research question: Is the INC1 Bare Metal Stent safe and effective for the treatment of de
      novo coronary lesions in humans? Hypothesis: The INC1 Bare-metal Stent is safe and effective
      for the treatment of de novo coronary lesions in humans

      The INC1 Bare metal Stent is a 70uCoCr
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2017</start_date>
  <completion_date type="Anticipated">January 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of late lumen loss [Safety and Tolerability])</measure>
    <time_frame>9 months</time_frame>
    <description>The primary endpoint of the study is angiographic in-stent late lumen loss (LLL), defined as the difference between the post-procedural minimal lumen diameter (MLD) in the stented segment and the MLD in the same segment at follow-up measured by the angiography laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need of Revascularization</measure>
    <time_frame>9 months</time_frame>
    <description>The Need of Revascularization of the treated vessel with a new angioplasty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate the presence of major adverse cardiovascular events such (MACE) as cardiac death, myocardial infarction, new angina event or revascularization through surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperplasia</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate the degree of neointimal hyperplasia or at 9 months by intracoronary ultrasound.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stents</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Angioplasty</condition>
  <condition>Humans</condition>
  <condition>Coronary Angiography</condition>
  <condition>Angioplasty, Balloon, Coronary</condition>
  <condition>Treatment Outcome</condition>
  <arm_group>
    <arm_group_label>INC1-Bare metal stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent INC1</intervention_name>
    <description>Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.</description>
    <arm_group_label>INC1-Bare metal stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders.

          -  From 18 to 75 years

          -  Stable ischemic heart disease.

          -  Live less than 300 km from the Institution

          -  Single coronary artery disease with a single coronary lesion

          -  Stenosis of 50 to 90% of the lumen of the vessel to be treated.

          -  Lesions less than 20 mm long

          -  Reference lumen of the vessel to be treated greater than 2.5mm and less than 4.5mm

        Exclusion Criteria:

          -  Left main disease.

          -  Lesions greater than 90% of the lumen.

          -  Non-dilatable lesion with conventional balloons.

          -  Contraindication for dual antiplatelet therapy.

          -  Creatinine clearance less than 45ml / min.

          -  Calcification from moderate to severe.

          -  Multivessel coronary artery disease.

          -  Chronic total occlusion.

          -  Cardiogenic shock or hemodynamic instability.

          -  Left ventricular ejection fraction less than 30%.

          -  Valvular disease of moderate to severe.

          -  Coronary disease in bifurcation.

          -  Probable or definite presence of thrombus in the lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Manuel Jiménez Rodríguez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interventional Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Manuel Jiménez Rodríguez</last_name>
    <phone>5591999962</phone>
    <email>gianma21@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian M Jiménez Rodríguez, Master</last_name>
      <phone>5591999962</phone>
      <email>gianma21@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arturo Abundes Velasco, Dr</last_name>
      <email>abundesva@yahoo.com.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Arturo Abundes Velasco, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco A Martínez Ríos, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco A Peña Duque, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Gaspar Hernández, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guering Eid Lidt, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Damas de los Santos, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yigal Piña Reyna, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Arias Sánchez, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</investigator_affiliation>
    <investigator_full_name>Gian Manuel Jiménez Rodríguez</investigator_full_name>
    <investigator_title>Clinical investigator assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

